Boston

Takeda inks value-based rebate deal for lung cancer drug – Boston, Massachusetts

Boston, Massachusetts 2021-10-20 09:00:44 –

Men Another bid to deal with the cost of prescription drugs, Takeda (TAK) And 32Point Health have reached an agreement that the drug company will offer a “significant refund” for lung cancer treatment if the drug turns out to be ineffective for the patient.

Specifically, the transaction includes Alunbrig, which is approved for the treatment of non-small cell lung cancer. Takeda will refund an unspecified amount to the insurance company if a patient covered by 32 Point Health, New England’s second largest health insurance, does not take the drug for more than 3 months for efficacy or tolerability To do. The list price for this drug is $ 17,000 for a month of treatment.

Sign up for STAT + to unlock this article and enjoy the first 30 days for free!

let’s start



Takeda inks value-based rebate deal for lung cancer drug Source link Takeda inks value-based rebate deal for lung cancer drug

Back to top button